NASDAQ
5.98USD
+0.13 (+2.22%)
We have scored 9 news catalysts on Abeona Therapeutics Inc. (ABEO) over the past 12 months. The biggest single-day move next to one of them came Oct 29, 2025, when ABEO closed −5.5%: “SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of DarioHealth Corp. (NASDAQ: DRIO)”. Coverage across the window leans negative (average ticker sentiment −0.44). Most of the impact sits in institutional appeal and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Latest scored catalyst for ABEO: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Market cap
340.8M
P/E
—
EPS
—
Beta
1.34
52W range
4-7.65
Day range
5.79–6.00
Open
5.80
Prev close
5.85
Volume
683K
Avg volume
1.3M
Dividend
0.00
IPO
1980-09-19
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Abeona Therapeutics Inc. — not a sector bucket. Click an edge to see the articles that established the link.
